Zevra Therapeutics Inc (NASDAQ:ZVRA) has a beta value of 1.95 and has seen 0.6 million shares traded in the recent trading session. The company, currently valued at $420.43M, closed the recent trade at $7.99 per share which meant it lost -$0.07 on the day or -0.87% during that session. The ZVRA stock price is -12.02% off its 52-week high price of $8.95 and 51.31% above the 52-week low of $3.89. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.14 million shares traded. The 3-month trading volume is 920.64K shares.
The consensus among analysts is that Zevra Therapeutics Inc (ZVRA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.4.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zevra Therapeutics Inc (NASDAQ:ZVRA) trade information
Sporting -0.87% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ZVRA stock price touched $7.99 or saw a rise of 10.73%. Year-to-date, Zevra Therapeutics Inc shares have moved 21.98%, while the 5-day performance has seen it change 2.70%. Over the past 30 days, the shares of Zevra Therapeutics Inc (NASDAQ:ZVRA) have changed 10.06%. Short interest in the company has seen 3.83 million shares shorted with days to cover at 2.92.
Wall Street analysts have a consensus price target for the stock at $21, which means that the shares’ value could jump 61.95% from the levels at last check today. The projected low price target is $20.0 while the price target rests at a high of $22.0. In that case, then, we find that the latest price level in today’s session is -175.34% off the targeted high while a plunge would see the stock gain -150.31% from the levels at last check today.
Zevra Therapeutics Inc (ZVRA) estimates and forecasts
The company’s shares have gained 36.82% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -6.80%.
6 analysts offering their estimates for the company have set an average revenue estimate of 5.2M for the current quarter. 6 have an estimated revenue figure of 12.52M for the next ending quarter. Year-ago sales stood 2.9M and 13.22M respectively for this quarter and the next, and analysts expect sales will grow by 79.60% for the current quarter and -6.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 51.89% over the past 5 years.
ZVRA Dividends
Zevra Therapeutics Inc is expected to release its next earnings report on 2024-Nov-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Zevra Therapeutics Inc (NASDAQ:ZVRA)’s Major holders
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. As of Aug 31, 2024, the former fund manager holds about 26.12% shares in the company for having 1.13 shares of worth $8.92 million while later fund manager owns 1.05 shares of worth $8.33 million as of Jun 30, 2024, which makes it owner of about 24.39% of company’s outstanding stock.
